CJC-1295

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). Its peptide core is a modified GHRH(1-29) sequence — the same active fragment as sermorelin — carrying amino-acid substitutions that resist enzymatic degradation, so it stimulates GH and IGF-1 secretion for longer than native GHRH. [1][3]

Two forms appear in the literature. The “No-DAC” form (often called Modified GRF 1-29) is the bare, stabilised GHRH(1-29) analogue with a relatively short half-life, used when researchers want a discrete, shorter GHRH stimulus. The “DAC” form adds a Drug Affinity Complex — a reactive linker that binds covalently to circulating albumin — which extends the half-life to roughly a week. [1] The material described here is the No-DAC form.

In a study in healthy adults, administration of CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 over a prolonged period, consistent with its design as a long-acting GHRH-receptor agonist that amplifies the body's own pulsatile GH output rather than supplying exogenous GH. [1]

CJC-1295 has been characterised analytically (for example by LC-HRMS/MS) in the anti-doping literature, where it was identified in an unknown pharmaceutical preparation, and it is listed as a prohibited substance by WADA owing to its GH-releasing activity. [2] This analytical work makes it a reference analyte in sports-testing method development.

CJC-1295 is a research compound, not an approved medicine. The material supplied here is intended solely for in-vitro and laboratory study by qualified professionals — it is not formulated, dosed, or authorised for use in humans or animals, and nothing here is a therapeutic claim.